COMMUNIQUÉS West-GlobeNewswire

Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib

27/11/2018 - 12:00

SAN DIEGO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submissions of the LeukoStrat ® CDx FLT3 Mutation Assay to both the US FDA and [...]

ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium

27/11/2018 - 10:47

SINGAPORE, Nov. 27, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in [...]

Transactions in relation to share buyback program

27/11/2018 - 10:15

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Aino Health AB (publ): Aino Health signs agreement with leading wholesaler

27/11/2018 - 08:45

27 November 2018 Aino Health has signed an end user agreement providing Aino HealthManager to one of the largest grocery wholesalers in Finland, with over 20 percent of the market share. The agreement encompasses over [...]

Rule 2.9 Announcement

27/11/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 27 November 2018 [...]

Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)

27/11/2018 - 07:16

Biosimilar Ziextenzo ® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1] Ziextenzo is indicated to reduce duration of [...]

Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London

27/11/2018 - 07:00

Alcon is the global leader in the highly attractive and growing $23 billion eye care devices market Market leading development capabilities and innovation investments Clearly defined near and long-term strategy, focused [...]

Sensorion Announces Completion of Patient Enrollment and Dosing in Seliforant Phase 2a Study

27/11/2018 - 07:00

First results are expected by the end of the year MONTPELLIER, France, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN) , a clinical-stage biopharmaceutical company specializing in the treatment of [...]

Amarin Prices Public Offering of American Depositary Shares

27/11/2018 - 02:59

BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced the pricing of the underwritten public offering of its American Depositary Shares ("ADSs") [...]

FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)

27/11/2018 - 01:16

First treatment with a tumor-agnostic indication at the time of initial FDA approval 75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR)] across various solid [...]

Oxford Immunotec to Participate in Two Investor Conferences This Week

26/11/2018 - 23:31

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief [...]

Akorn Receives Product Approval

26/11/2018 - 23:29

LAKE FOREST, Ill., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a new Abbreviated New Drug Application (ANDA) approval from [...]

Canopy Rivers Reports Second Quarter Financial Highlights and Provides Corporate Update

26/11/2018 - 23:01

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (the “ Company ” or “ Canopy Rivers ”) (TSXV: RIV) today released its financial results [...]

XORTX Receives FDA Response on Orphan Drug Designation Application

26/11/2018 - 23:00

Pivotal Phase 2/3 Clinical Study in ADPKD Planned in 2019 CALGARY, Alberta, Nov. 26, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company [...]

Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors

26/11/2018 - 22:41

WARMINSTER, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Frank Torti has been [...]

IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018

26/11/2018 - 22:35

DARTMOUTH, Nova Scotia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will present data on its DPX-RSV program at “ RespiDART: [...]

Molecular Templates to Present at the Evercore ISI and BMO Healthcare Conferences

26/11/2018 - 22:30

AUSTIN, Texas, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies [...]

Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer

26/11/2018 - 22:30

COLUMBIA, Md., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, [...]

Abeona Therapeutics Announces CEO Transition

26/11/2018 - 22:30

Dr. Carsten Thiel to Depart Company Immediately; Dr. João Siffert Appointed Interim CEO NEW YORK and CLEVELAND, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage [...]